📊 Q3 Earnings are here! Plan ahead with key data on upcoming stock reports - all in 1 placeSee list

Galectin Therapeutics Inc (GALT)

NASDAQ
Currency in USD
Disclaimer
2.630
-0.110(-4.01%)
Closed
After Hours
2.6300.000(0.00%)
GALT Scorecard
Full Analysis
Suffers from weak gross profit margins
Fair Value
Day's Range
2.6002.800
52 wk Range
1.5554.268
Prev. Close
2.74
Open
2.74
Day's Range
2.6-2.8
52 wk Range
1.555-4.268
Volume
91,037
Average Volume (3m)
121,917
1-Year Change
30.48%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
GALT Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
11.000
Upside
+318.251%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year
Show more

Galectin Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Compare GALT to Peers and Sector

Metrics to compare
GALT
Peers
Sector
Relationship
P/E Ratio
−3.4x−3.2x−0.6x
PEG Ratio
0.220.040.00
Price/Book
−1.9x1.5x2.6x
Price / LTM Sales
-2.2x3.3x
Upside (Analyst Target)
301.5%177.8%44.5%
Fair Value Upside
Unlock20.4%6.0%Unlock

FAQ

What Is the Galectin (GALT) Stock Price Today?

The Galectin stock price today is 2.63.

What Stock Exchange Does Galectin Trade On?

Galectin is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Galectin?

The stock symbol for Galectin is "GALT."

What Is the Galectin Market Cap?

As of today, Galectin market cap is 165.60M.

What is Galectin Earnings Per Share?

The Galectin EPS is -0.782.

What Is the Next Galectin Earnings Date?

Galectin will release its next earnings report on 10 Nov 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.